Clinical trial

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-02-20

PhasePHASE3

Study timeline

Study start (actual)2024-02-20Date precision: day

Registry last updated2026-04-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Limited Stage Small Cell Lung Cancerunresolved

Small Cell Lung Cancerunresolved

Interventions

TarlatamabDRUG · verified · RxNorm: tarlatamab

PlaceboDRUG

Sponsors & collaborators

Amgenlead sponsor

Mapped research locations

AthensGreece6 SeoulSouth Korea4 SofiaBulgaria4 AnkaraTurkey (Türkiye)4 BarcelonaCatalonia, Spain4 IstanbulTurkey (Türkiye)3 Porto AlegreRio Grande do Sul, Brazil3 WuhanHubei, China3 New YorkNew York, United States2 MadridSpain2 MilanItaly2 TaipeiTaiwan2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06117774 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.